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The use of the specific binding properties of monoclonal antibody fragments such as single-chain vari-
able fragments (ScFv) for the selective delivery of antitumor therapeutics for cancer cells is attractive due
to their smaller size, low immunogenicity, and low-cost production. Although covalent strategies for the
preparation of such ScFv-based therapeutic conjugates are prevalent, this approach is not straightforward,
as it requires prior chemical activation and/or modification of both the ScFv and the therapeutics for the
application of robust chemistries. A non-covalent alternative based on ScFv fused to maltose-binding
protein (MBP) acting as a binding adapter is proposed for active targeted delivery. MBP-ScFv proves to be
a valuable modular platform to synergistically bind maltose-derivatized therapeutic cargos through the
MBP, while preserving the targeting competences provided by the ScFv. The methodology has been
tested by using a mutated maltose-binding protein (MBP I334W) with an enhanced affinity toward
maltose and an ScFv coding sequence toward the human epidermal growth factor receptor 2 (HER2).
Non-covalent binding complexes of the resulting MBP-ScFv fusion protein with diverse maltosylated
therapeutic cargos (a near-infrared dye, a maltosylated supramolecular β-cyclodextrin container for
doxorubicin, and non-viral polyplex gene vector) were easily prepared and characterized. In vitro and
in vivo assays using cell lines that express or not the HER2 epitope, and mice xenografts of HER2 expres-
sing cells demonstrated the capability and versatility of MBP-ScFv for diagnosis, imaging, and drug and
plasmid active targeted tumor delivery. Remarkably, the modularity of the MBP-ScFv platform allows the
flexible interchange of both the cargos and the coding sequence for the ScFv, allowing ad hoc solutions
in targeting delivery without any further optimization since the MBP acts as a pivotal element.
1. Introduction
Nanomedicine offers new tools for diagnosis, prevention, and
treatment of diseases.1,2 In particular, cancer nanomedicine is
rapidly becoming one of the leading areas of promise that rely
mainly on the use of nanomaterials for targeted cancer
therapy3 to overcome the limitations of conventional cancer
chemotherapy.4–6 Active targeting requires the use of ligands
that specifically recognize cancer cell receptors/biomarkers,
triggering their docking and/or precise internalization.
Targeted antitumor therapeutics (TATs) are constructed by
either direct coupling of the therapeutic to the ligand targeting
moiety or by conjugation to a soluble or insoluble nanoparticle
carrier (NP) to load therapeutics.7,8 Currently, a wide variety of
NPs are being investigated as platforms for cancer treatment,
including lipid-based, polymer-based, inorganic, and viral con-
jugated nanoparticles.9
Amongst the different targeting ligands (antibodies, pep-
tides, hormones, nucleic acids, and lipid derivatives), mono-
clonal antibodies (mAb) are the most frequently used to
actively target tumor cells due to their high specificity and
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unique in vivo properties.10 Although the use of full-length
antibodies is advantageous in terms of pharmacokinetics,
certain inherent structural properties limit the applicability of
mAb-based TATs for cancer therapy.11 The large size of mAb
can hamper access to tumor cells, particularly in the treatment
of solid tumors. To circumvent the shortcoming associated
with full-sized mAb, antibody fragments have been introduced
for the preparation of TATs.12,13 The most commonly used
antibody fragments are single-chain variable fragments (ScFv)
that consist of the antibody variable domains connected by a
flexible linker. Although ScFv has a much lower binding
affinity compared to whole antibody counterparts due to the
use of a flexible link, and its blood half-life and stability are
lower than the whole antibody, it has an improved therapeutic
potential due to its smaller size, low immunogenicity, and low-
cost production.14,15
Functionalizing NPs with mAb or ScFv is currently per-
formed through a variety of covalent and non-covalent
methodologies.16,17 Although mAb-NPs conjugates obtained
through covalent strategies are prevalent due to their high
stability, this is not a straightforward approach as it usually
requires prior chemical activation of NPs and/or the chemical
modification of the mAb or ScFv for the application of robust
chemistries (carbodiimide, maleimide, and “click” chemistry).
Furthermore, covalent functionalization depends on the
nature of the protein and its amino acid composition and
therefore it is difficult to standardize a functionalization
method valid for any mAb or ScFv. Therefore, optimization in
each case of the covalent functionalization is a time-consum-
ing process.18 In contrast, less used non-covalent approaches
rely on the use of physical adsorption, ionic bonding, or
binding to an adapter molecule.19 The most relevant binding
strategy based on an adapter molecule exploits the biotin–
avidin interaction, being commonly implemented by biotinyla-
tion of the mAb/ScFv and functionalization of the NP with
avidin or its analogs. Recently, a pre-targeting approach based
on mAb-streptavidin fusion proteins has attracted considerable
attention because of its modularity and improved cellular
internalization.20,21
Recombinant ScFv can be produced in a variety of different
systems ranging from bacteria to mammalian cells. However,
in bacteria, several technical difficulties have to be addressed
due to the reducing environment of the cytoplasm that causes
misfolding of ScFv and the formation of inclusion bodies
affecting ScFv stability. To solve this critical issue, different
engineering approaches have been envisioned.22 Remarkably,
the cytoplasmic expression of ScFvs as a C-terminal fusion to
maltose-binding protein (MBP) provides a general solution,
allowing a high-level production of stable, soluble, and func-
tional MBP-ScFv fusion protein (MBP-ScFv).23,24 MBP is a part
of the maltose/maltodextrin system of E. coli, which is respon-
sible for the uptake and efficient catabolism of maltodextrins,
and one of the most popular fusion partners used for produ-
cing recombinant proteins in bacterial cells. In this scenario,
MBP functions as a molecular chaperone and a tag for maltose
(Mal) based affinity purification of ScFv. Upon purification,
the MBP tag is cleaved by a specific protease to obtain
untagged ScFvs that are further used, including their appli-
cations in TATs.
To avoid the need for chemical conjugation of the targeting
moiety in NPs, we proposed a novel strategy where the
MBP-ScFv recombinant protein is not proteolytically processed
but is directly used as a soluble NP. By using the whole fusion
protein, the MBP moiety of an MBP-ScFv is used as a binding
adapter molecule for the incorporation of Mal-containing
therapeutic cargos while preserving the functionality of the
Fig. 1 MBP-ScFv recombinant protein as a platform for the delivery of
therapeutic cargos. (A) Diverse maltosylated cargos bind to the
MBP-ScFv through the MBP active center. The resulting complexes are
directed by the ScFv to cells bearing complementary receptors. (B)
HER2 expression in cell lines. HER2 was measured by western blot using
either biotin-labeled transtuzumab or biotin-labeled MBP*-ScFv. A
representative blot as well as the quantitation of the intensity of the
detected bands are shown. Data are shown as means ± SEM (n = 4). *p <
0.05 vs. band intensity of MDA-MB-231 cells. (C) Fluorescence of
unbound (IR783)Mal and binding complexes of (IR783)Mal to MBP based
proteins.
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ScFv as the targeting ligand for the specific recognition of
antigen-bearing cells (Fig. 1A). We herein demonstrate the val-
idity of our proposal in combination with the easy vinyl
sulfone click-chemistry Mal glycosylation of the desired cargo,
a methodology previously developed by us.25,26 This strategy
prevents the need for covalent conjugation methodologies for
the functionalization of NPs and can be used with any
MBP-ScFv construct without the need for new chemical
reagents. This is a modular and versatile approach, since by
changing the maltosylated ligands, it is possible to generate
NPs with the capability to visualize, transport or deliver genes.
On the other hand, by just changing the coding sequence of
the ScFv included in the expression plasmid, it is possible to
target different surface receptors without any further optimiz-
ation. As a proof of concept, a ScFv toward the human epider-
mal growth factor receptor 2 (HER2) was expressed as an
MBP-ScFv containing a poly histidine affinity tag to allow puri-
fication. The platform was employed for the binding of a mal-
tosylated NIR dye, a maltosylated supramolecular container of
doxorubicin, and a maltosylated non-viral polyplex gene
vector. The corresponding binding complexes were assayed
in vitro and in vivo to test their capability for diagnosis and
imaging, specific chemotherapeutic, and plasmid active tar-
geted tumor delivery.
2. Materials and methods
2.1. General experimental procedures
Branched polyethylenimine 2 kDa and 25 kDa (2kPEI and
25kPEI), doxorubicin hydrochloride (DOX) and indocyanine
green (ICG) were purchased from Merck (Madrid, Spain).
Lipofectamine™ 2000 (LP) came from Invitrogen (Carlsbad, CA,
USA). pEGFP-N3 plasmid (Genbank U57609), which encodes for
an enhanced red-shifted variant of wild-type GFP (eGFP), was
obtained from Clontech Laboratories (Palo Alto, CA). pGL3-
control vector (Genbank U47296.2) expressing luciferase under
the SV40 enhancer promoter was obtained from Promega
(Mannheim, Germany). Endotoxin-free plasmids were purified
from transformed bacteria using the EndoFree plasmid Maxi kit
from Quiagen (Hilden, Germany). DNA concentration was
measured by a fluorimetric method using the Hoechst 33258
dye. Trastuzumab (Herceptin) was offered by the Oncology
Pharmacy at Cádiz General Hospital (Cádiz, Spain).
2.2. Expression and purification of MBP-HER2 ScFv fusion
proteins (MBP-ScFv)
Expression. pACgp67B-HER2 plasmid containing the coding
sequence for ML39 HER2 ScFv was a gift from Judy Lieberman
(Addgene plasmid # 10794).27 ScFv coding sequence including a
3′-polyhistidine tail was amplified from pACgp67B-HER2 by
PCR adding 5′BamHI and 3′HindIII restriction sites. A PCR frag-
ment was sub-cloned in pMAL-TEV vector, a modified pMAL-
c2X expression vector (New England Biolabs, Ipswich, MA, USA)
where the factor Xa cleavage site has been substituted by a TEV
protease cleavage site,28 to generate pMAL-TEV-ScFv HER2-His
plasmid for the bacterial expression of a MBP-ScFv fusion
protein. Site-directed mutagenesis of the MBP has been carried
out as described previously,29 to introduce an I334W mutation
in the MBP coding sequence generating plasmid
pMALI334W-TEV-ScFv HER2-His. The oligonucleotides used are
indicated in the ESI, Table 1.† Novagen’s Rosetta™ 2 competent
cells (Merck, Madrid, Spain) were transformed either with
plasmid pMALI334W-TEV-ScFv HER2-His or with the empty
vector pMALI334W-TEV-His, and were grown in Luria–Bertani
Broth medium with selection antibiotics at 37 °C. Cells were
incubated (OD600 = 0.5) with 0.5 mM IPTG to induce the
protein expression at 30 °C for an additional period of 6 h. The
bacteria pellet was stored at −20 °C.
Purification. Bacteria pellets were re-suspended in 20 mM
HEPES, 10% glycerol, 0.2% Triton X-100, pH 8 buffer contain-
ing 1 mM PMSF and 100 µg ml−1 of lysozyme and sonicated.
The lysed bacteria suspension was centrifuged for 30 min at
12 000g to remove cell debris. Protamine sulfate (0.1%) was
added to the supernatant and maintained for 30 min at 4 °C
while shaking. This suspension was centrifuged (30 min,
12 000g), and the supernatant was filtered through a 0.45 µm
filter. A HisTrap HP 1 ml column (GE Healthcare Life Sciences,
Chicago, IL, USA) was equilibrated in 20 mM HEPES, 20 mM
imidazole, 10% glycerol, 0.2% Triton X-100, pH 8 buffer, and
the supernatant was then loaded onto the column. After
washing, proteins were eluted using 20 mM HEPES, 500 mM
imidazole, 10% glycerol, 0.2% Triton X-100, pH 8. Eluted
samples were directly loaded onto a HiTrap Heparin HP 1 mL
column (GE Healthcare Life Sciences) equilibrated with
20 mM HEPES, 500 mM NaCl 10% glycerol, 0.2% Triton X-100,
pH 8. The column was washed with the same buffer and the
protein of interest was eluted using a 20 mM HEPES, 1 M NaCl
10% glycerol, 0.2% Triton X-100, pH 8. The eluted MBPI334W-
ScFv (MBP*-ScFv) and MBPI334W (MBP*) proteins were concen-
trated and buffer exchanged by centrifugation at 10 000g using
a PES (polyethersulfone) centrifugal filter (VWR International,
Barcelona, Spain) with a 20 mM HEPES, 120 mM NaCl pH 7.4
buffer. Protein concentration was measured by BCA method.
The fluorescence of unbound (IR783)Mal and binding com-
plexes of (IR783)Mal to MBP based proteins was assayed by
fluorimetry. Fluorescence spectra were recorded in a JASCO
FP-8300 spectrofluorometer with 2.5 nm band windows using
50 µM (IR783)Mal (20 mM Na Hepes, 120 mM NaCl buffer pH
7,4) and 10 µM of either BSA, MBP, MBP* or MBP*-ScFv.
Excitation was set at 550 nm.
2.3. Cell lines
Breast cancer cells HER2+ (SKBR3; ATCC HTB-30) and HER2−
(MDA-MB-231; ATCC HTB-26) were grown at 37 °C in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (v/v)
fetal bovine serum (FBS), 2 mM glutamine plus 100 U mL−1
penicillin, in an atmosphere of 5% CO2 and 95% air and main-
tained at sub-confluent densities in the growth media.
MDA-MB-231 cells overexpressing the HER2 receptor
(MDA-HER2+) were obtained by retroviral transduction using
Phoenix Ampho cells (kindly offered by Dr J. L. Garcia-Perez,
Paper Biomaterials Science

































































































Centre for Genomics and Oncological Research: Pfizer,
University of Granada, Granada, Spain), and the plasmid
pBABEpuro-ERBB2 (a gift from Matthew Meyerson, Addgene
plasmid # 40978).30 In brief, Phoenix-Ampho cells were seeded
in 6 well plates at a density of 2.3 × 105 cells per well for 24 h
to reach a cell confluence of 80–90%. Transfection was then
performed using pBABEpuro-ERBB2 and LP following manu-
factured instructions. Retroviral supernatants were collected
from sub-confluent cultures (48 h) and used to infect
MDA-MB-231 cells. Then, MDA-HER2+ cells were selected by
using 8 µg mL−1 puromycin. HER2 expression was confirmed
by western blot (Fig. 1) using biotin labeled herceptin, and a
high sensitivity streptavidin-HRP (Pierce, Rockford, IL, USA).
Herceptin labeling was done using a vinyl sulfone derivatized
bifunctional tag single-attachment-point reagent bearing
biotin and a fluorescent tag31 (supplementary, vinyl sulfone
based reagents). Alternatively, purified MBP*-ScFv was labeled
with the same reagent.
2.4. MBP*-ScFv imaging assays
Imaging and detection of breast cancer cells by Mal-based
ligands were evaluated by confocal microscopy using a Leica
TCS-SP5 II multiphoton confocal microscope following pre-
viously reported procedures32 that prevent cross-talk of fluoro-
phores by using distinct excitation laser lanes and non-overlap-
ping detection channels. In all cases, cells were first seeded
onto coverslips in 12-well plates (density equal to 9 × 105 cells
per well) and incubated at 37 °C (24 h) to reach a cell conflu-
ence of 80–90%. For cell uptake assays, DOX- or ICG-based
compounds were incubated for 2 h. Cells were fixed with paraf-
ormaldehyde (2% in PBS, 15 min at room temperature),
washed and mounted for confocal microscopy. For detection
of HER2 positive cells, HER2 expressing SKBR3 cells or HER2
negative MDA-MB-231 cells were seeded onto coverslips and
24 h later they were fixed and incubated with [(IR783)
Mal]∼[MBP*-ScFv], washed and mounted.
2.5. Targeted drug delivery assays
Doxorubicin cell uptake. DOX or ICG, and 2kPEI(CD)Mal
(molar ratio n : nCD = 0 : 9) were incubated overnight at 4 °C to
produce the corresponding inclusion complexes 2kPEI
(DOX⊂CD)Mal or 2kPEI(ICG⊂CD)Mal. After freeze-drying, for-
mation of the complexes was confirmed using UV-Vis and fluo-
rescence spectroscopy. 2kPEI(DOX⊂CD)Mal or 2kPEI
(ICG⊂CD)Mal were incubated with equimolecular amounts of
MBP*-ScFv or MBP* (considering the number of Mal mole-
cules in the complexes and Mal binding sites in the proteins)
for 30 min at room temperature. Then, MDA-MB-231,
MDA-HER2+ or SKBR3 cells were incubated, with concen-
trations corresponding to 1 µM DOX, with DOX, 2kPEI
(DOX⊂CD)Mal, 2kPEI(DOX⊂CD)Mal∼[MBP*] or [2kPEI
(DOX⊂CD)Mal]∼[MBP*-ScFv] for 2 h. Cells were lysed with
200 μL of 0.5% Triton X-100 in PBS and the fluorescence due
to DOX was measured in a JASCO FP-8300 spectrofluorometer
with 2.5 nm band windows at 499 nm excitation and 555 nm
emission wavelengths.
Cytotoxicity of DOX inclusion complex. MDA-MB-231,
MDA-HER2+ or SKBR3 cells were incubated for 48 h, with equi-
molecular concentrations corresponding to 1 µM DOX, with
DOX, 2kPEI(DOX⊂CD)Mal, 2kPEI(DOX⊂CD)Mal∼[MBP*] or
[2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv]. Also, similar concen-
trations of 2kPEI-Mal, MBP* or MBP*-ScFv were used. Cell via-
bility was measured by a MTT assay as previously reported.32
2.6. Targeted gene delivery assays
Gel electrophoresis shift assay. A mixture of pEGFP-N3 DNA
(5 μL at 0.1 mg mL−1) and 25kPEI or 25kPEI(Mal) was incu-
bated for 30 min at room temperature. The 25kPEI(Mal) poly-
plex was then incubated with MBP* or MBP*-ScFv for an
additional 20 min. An aliquot (5 µL) of each mixture was run
in agarose gel electrophoresis (0.8% w/v) using TAE buffer
(40 mM, Tris-acetate, 1 mM EDTA). The electrophoresis was
carried out as described.33
DNase protection assay. pEGFP-N3 DNA (10 μL at 0.1 mg
mL−1) and 25kPEI or 25kPEI(Mal) were mixed to obtain solu-
tions of N/P ratios of 1, 2 and 4 that were incubated for 30 min
at room temperature. The resulting polyplexes were incubated
with MBP* or MBP*-ScFv for an additional 20 min and then a
solution of DNase I (10 μL, 50 μg mL−1 in Tris HCl 50 mM pH
8) was added and incubated for 1 h at 37 °C. After the diges-
tion, SDS (2 μL of a 10% solution) was added and the samples
were incubated for 15 min at 65 °C before the addition of
loading buffer (4 μL). Finally, an aliquot (20 μL) of each
sample was subjected to agarose gel electrophoresis (0.8% w/v)
in TAE buffer. Quantification of the band intensity was per-
formed with the NIH Image Software. A value of 100 was
assigned to the intensity of the band corresponding to the
control undigested DNA.
Transfection assay. Prior to transfection, cells were seeded
in 48 well plates at a density of 1.5 × 104 cells per well for 24 h
to reach a cell confluence of 80–90%. Then, pEGFP-N3
plasmid (0.3 μg per well) was mixed with 25PEI or 25kPEI(Mal)
(N/P ratio = 7) and incubated at room temperature for 20 min
to form the corresponding polyplexes. MBP* or MBP*-ScFv
were added in a concentration equimolecular with the amount
of Mal in the 25kPEI(Mal), and the mixture was incubated for
an additional 30 min at room temperature. It was finally
diluted to 0.2 mL with DMEM without serum and added to
each well. Five hours later, the transfection media was
removed and cells were further grown in DMEM plus 10% FBS
for an additional period of 24 h. As a negative control, non-
transfected cells were used. As a positive control, LP was used
by forming polyplexes using 0.6 μL of LP and 0.3 µg of DNA,
according to the manufacturer’s instructions. Fluorescence
and protein assays of transfected cells were performed follow-
ing previously reported procedures.33
2.7. In vivo studies
Female NSG immunodeficient mice (6–8 weeks of age, 25–30 g
weight) were purchased from the Animal Facility at the
University of Granada and maintained in accordance with
guidelines established by Directive 2012/707/UE and the
Biomaterials Science Paper

































































































approval of the Committee on Animal Research at the
University of Granada (15/11/2017/154). For xenografts models,
SKBR3 cells were trypsinized and re-suspended in PBS (density
equal to 2 × 107 cells per mL). Cells (1 × 106) were injected
intradermally into the breast area of each female NSG mouse.
When tumor sizes reached 1 to 6 mm in diameter, mice were
injected in the tail vein with the different targeted antitumor
therapeutics. The in vivo imaging over time assays were per-
formed in an IVIS Spectrum (xCaliper Life Sciences, MA, USA).
Isofluoran-anesthetized mice were placed in the dark chamber
for luminiscence or fluorescence (excitation/emission, 675/
720 nm) acquisition. Images were taken and analyzed with the
Living Image 2.6 software package (Xenogen).
Imaging assays. For HER2+ cells detection, MBP*-ScFv was
incubated with equimolecular amounts of (IR783)Mal for
30 min to induce the formation of [(IR783)Mal]∼[MBP*-ScFv]
complex. As a negative control, an equivalent amount of 5 µM
solution of (IR783)Mal was used. The therapeutics were
injected in the tail vein. In vivo imaging was performed 24 h
later.
Targeted drug delivery assays. Since DOX spectra does not
allow in vivo detection in tumor-bearing animal models, the
treatment of the mice was simulated by using [2kPEI(ICG⊂CD)
Mal] that was incubated with equimolecular amounts of
MBP*-ScFv for 30 min at room temperature to get the [2kPEI
(ICG⊂CD)Mal]∼[MBP*-ScFv] complex. As a negative control,
[2kPEI(ICG⊂CD)Mal]∼[MBP*] complex was used. Complexes
were injected in the tail vein and in vivo monitoring was per-
formed for 30 min.
Targeted gene delivery assays. pGL3 control plasmid (50 μg)
was complexed with 25kPEI(Mal) (N/P ratio = 7) by incubation
for 20 min. Then, equimolecular amounts of MBP* or MBP*-
ScFv were added for an additional period of 30 min. Tumor-
bearing NSG mice were injected via the tail vein. The in vivo
imaging over time assays were performed 24 hours later in
mice injected intraperitoneally with 150 mg kg−1 of D-luciferin
(Melford Laboratories, Chelsworth, UK).
2.8. Statistical analysis
Results are expressed as mean ± SEM. Statistical analysis was
performed by two-way ANOVA followed by Tukey’s test as
appropriate. P < 0.05 was considered statistically significant.
3. Results
3.1. Design, expression, purification and study of the
functionalization of MBP-ScFv
The overexpression of the protein of interest as a fusion
protein bearing a peptide/protein tag is a well-established
strategy to facilitate its isolation.34 Different systems are com-
mercially available and they rely on the reversible affinity of
the tag for chromatographic matrix. We hypothesized that this
affinity can be further exploited in the context of antibody–
drug conjugates and we envisioned a two-tag platform bearing
a His-tag for purification purposes and a maltose binding
protein (MBP) tag as an attachment point of different elements
that carry a maltose motif (Fig. 1A).
However, for our purpose, the reversibility of the interaction
between MBP tag and maltose was undesired and the wild type
MBP tag was mutated to yield MBPI334W (MBP*) tag. The
mutation is located at the hinge region that bends upon sub-
strate binding to form the active site of the protein and MBP*
exhibits enhanced ligand affinity (approximately 5 fold) and a
decrease of the ligand Koff, without hampering its solubility
and stability (unpublished data).
To test our hypothesis, the DNA encoding ScFv against
HER2 was cloned between both tags to generate the plasmid
pMALI334W-TEV-ScFv HER2-His. The overexpression in E. coli
yielded the soluble recombinant protein MBP*-ScFv that was
isolated by Ni2+-based IMAC chromatography and further puri-
fied by heparin chromatography to a final yield of 0.5 mg of
protein per liter of culture (Fig. S1, ESI†).
The ability of MBP*-ScFv to recognize the HER2 epitope was
assessed by western blot in HER2+ cell extracts such as SKBR3
and MDA-HER2+, using the HER2− cell line MDA-MB-231 as
negative control, and Trastuzumab, the commercial antibody
against HER2, as reference. As shown in Fig. 1B, both MBP*-
ScFv and trastuzumab only recognized the HER2+ extracts and
the intensity of the signal was in the same range for
MDA-HER2+ and lower for SKBR3.
The functionality of the MPB* tag as an attachment point
was studied using the NIR dye IR783 functionalized with
maltose via a vinyl sulfone-based click strategy by the reaction
of IR783 piperazine35 with vinyl sulfone maltose.25 As a
cyanine-based fluorophore, in aqueous solution (IR783)Mal
tends to self-assemble into aggregates, resulting in a quench-
ing of the fluorescence that is restored upon disassembly.36
This feature was exploited to assess the interaction of MBP*-
ScFv with the maltose-bearing element. As shown in Fig. 1C,
the fluorescence of (IR783)Mal alone is quenched and neglect-
able. Both MBP and MBP* promoted the disaggregation, and
the resulting fluorescence for MBP* was slightly blue-shifted
and larger, as expected from the higher affinity resulting from
the I334W mutation. As a tag, MBP*-ScFv was fully functional
and the interaction with (IR783)Mal yielded a value of fluo-
rescence similar to free MBP despite being fused to ScFv.
3.2. MBP*-ScFv complexes as specific imaging agents
A simultaneous evaluation of the capability of MBP*-ScFv to
both recognize HER2 and form a complex with an element
bearing the maltose moiety was carried out using (IR783)Mal
as a probe. The combination of equimolecular amounts of
MBP*-ScFv and (IR783)Mal yielded [(IR783)Mal]∼[MBP*-ScFv],
which was assayed against the HER2+ SKBR3 cells and the
HER2− MDA-MB-231 cells. As depicted in Fig. 2, SKBR3 cells
showed a red fluoresce that was 5.7-fold more intense than
that of MDA-MB-231, supporting the functionality of MBP*-
ScFv and the feasibility of [(IR783)Mal]∼[MBP*-ScFv] as a diag-
nostic agent to detect HER2+ overexpressing cells. Further
evaluation of mice bearing HER2+ xenografts showed that the
fluorescence was located in both the xenograft and liver
Paper Biomaterials Science

































































































(Fig. 3A), with an intensity 16-fold and 3-fold higher respect-
ively, when (IR783)Mal was attached to MBP*-ScFv (Fig. 3B).
Analysis of the liver revealed the presence of metastasis that
were labeled with [(IR783)Mal]∼[MBP*-ScFv] (Fig. 3C). These
results demonstrate the functionality of MBP*-ScFv and the
preferential concentration of [(IR783)Mal]∼[MBP*-ScFv] in
tumors, supporting the feasibility of using complexes of suit-
able dyes with MBP*-ScFv as in vivo diagnostic agents to detect
HER2+ overexpressing cells.
3.3 MBP*-ScFv complexes for targeted chemotherapeutic
delivery
Inspired from a previous paper describing a modular design of
site-directed drug delivery systems that decouples the carrier
function from the targeting function,37 MBP*-ScFv was evalu-
ated as the targeting module. A multivalent carrier module
was designed through a combination of branched polyethyl-
enimine 2 kDa (2kPEI) as a scaffold, β-cyclodextrin (βCD) as
host, and maltose as the link to allow the coupling to MBP*-
ScFv. 2kPEI and maltose vinyl sulfone were first reacted in a
1 : 1 ratio and then with 4 equivalents of βCD vinyl sulfone to
obtain 2kPEI(CD)Mal. The incubation of 2kPEI(CD)Mal with
doxorubicin (DOX) in a 1 : 3.6 ratio led to the formation of
inclusion complexes termed 2kPEI(DOX⊂CD)Mal, as pre-
viously described.38 Then, the combination of 2kPEI
(DOX⊂CD)Mal with equimolecular amounts of MBP*-ScFv
yielded [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv]. Despite the limit-
ations and clinical relevance of DOX, its election as a model
drug was based on the fact that its fluorescence allows the
detection of [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv]. The capa-
bility of [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv] to deliver DOX
was evaluated in vitro. Confocal microscopy (Fig. 4A and B)
and fluorimetric quantitation of the DOX uptake (Fig. 4C) were
carried out. HER2+ (MDA-HER2+ and SKBR3) and HER2−
(MDA-MB-231) cells were selected for these assays. In HER2+
cells, DOX uptake was significantly higher when cells were
incubated with the [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv]
complex compared to DOX alone or 2kPEI(DOX⊂CD)Mal.
Furthermore, uptake was significantly decreased when DOX
was occluded in 2kPEI(CD)Mal (i.e. the carrier module without
the targeting module) or administrated as a [2kPEI(DOX⊂CD)
Mal]∼[MBP*] complex (i.e. the carrier module with the attach-
ment point but without the targeting function) compared to
DOX. Similar results were obtained when the samples were
assayed by flow cytometry (Fig. S2, ESI†). More interestingly,
when the toxicity associated with the DOX administration was
analyzed (Fig. 4D), the toxic effect of DOX as [2kPEI(DOX⊂CD)
Mal]∼[MBP*-ScFv] was more pronounced than that of free
DOX on HER2+ cells but less efficient in HER2− cells.
To evaluate the potential of [2kPEI(DOX⊂CD)Mal]∼[MBP*-
ScFv] as a site-directed drug delivery system, an in vivo analysis
Fig. 2 In vitro imaging of HER2+ cells by [(IR783)Mal]∼[MBP*-ScFv]
complex. HER2+ SKBR3 cells (A) or HER2− MDA-MB-231 cells (B) were
seeded onto coverslips, fixed, incubated with [(IR783)Mal]∼[MBP*-ScFv]
complex, washed, and mounted for confocal microscopy. Fluorescence
(a), differential interference contrast (Nomarski) images (b), and merged
images (c) are shown. (C) The average of the fluorescence/µ2 assigned
to the cells is plotted. Data are shown as means ± SEM (n = 10). *p <
0.05 vs. fluorescence of MDA-MB-231 cells.
Fig. 3 In vivo imaging of tumor HER2+ xenografts in mice by [(IR783)
Mal]∼[MBP*-ScFv] complex. NSG mice bearing breast cancer HER2+
(SKBR3 cells) tumors were injected intravenously in the tail vein with
(IR783)Mal or [(IR783)Mal]∼[MBP*-ScFv] and fluorescence was
measured 24 h later. (A) NIR fluorescence images. The size of the xeno-
grafts is indicated by a dotted line. (B) Average radiance of the xenografts
and liver metastases from the mice injected with (IR783)Mal or [(IR783)
Mal]∼[MBP*-ScFv]. Data are shown as means ± SEM (n = 4). *p < 0.05
vs. (IR783)Mal xenografts or livers metastases. (C) Fluorescence imaging
of dissected xenografts and livers metastases.
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was carried out using immune-suppressed NSG mice bearing
breast cancer HER2+ (SKBR3 cells) xenografts (Fig. 5). Since
in vivo imaging systems are not optimal for detecting DOX due
to the relatively low wavelength of its fluorescence emission,
indocyanine green (ICG), a cyanine IR dye used in medical
diagnostics,39 was assayed as a model drug. ICG was hosted in
2kPEI(CD)Mal and then complexed with either MBP* or MBP*-
ScFv, to obtain [2kPEI(ICG⊂CD)Mal]∼[MBP*] or [2kPEI
(ICG⊂CD)Mal]∼[MBP*-ScFv]. To test the validity of this
approach, the (ICG⊂CD) inclusion complex distribution was
first analyzed in vitro in SKBR3 cells by confocal microscopy
(Fig. 5A). It was observed that ICG entered the cells and that
the uptake was higher when cells were incubated with [2kPEI
(ICG⊂CD)Mal]∼[MBP*-ScFv] in regard to [2kPEI(ICG⊂CD)
Mal]∼[MBP*], supporting the results obtained with DOX. In
animals, the analysis of fluorescence distribution 30 min after
the injection in the tail vein revealed that only [2kPEI
(ICG⊂CD)Mal]∼[MBP*-ScFv] was visible in the xenograft,
although a significant amount of signal was located in the
liver. Quantification of the fluorescence in the xenograft
yielded a 7-fold higher fluorescence when ICG was targeted by
MBP*-ScFv compared to MBP*. The above results with DOX
and with ICG demonstrate the versatility of 2kPEI(CD)Mal as a
carrier module and the feasibility of using MBP*-ScFv as a tar-
geting module.
3.4. MBP-ScFv complexes for targeted gene delivery
The use of PEI for gene transfection is a well-established meth-
odology that works in vitro but the lack of specificity compro-
mises the implementation in vivo.40 Additionally, the size of
PEI is a critical factor to consider, since low molecular weight
PEIs are ineffective while highly branched PEIs show signifi-
cant toxicity. In this context, receptor-mediated site-directed
delivery is an attractive approach and we hypothesized that the
maltosylation of PEI is a feasible approach to link to the target-
ing module MBP*-ScFv while preserving the transfection
activity. Branched polyethylenimine 25kPEI (25kPEI) was
reacted with vinyl sulfone maltose using a 1 : 5 25kPEI/Mal
stoichiometry ratio to get a multi-maltosylated PEI derivative,
named 25kPEI(Mal), to maximize its binding capabilities to
Fig. 4 In vitro targeted DOX delivery and cytotoxicity mediated by a MBP*-ScFv binding complex. (A) Confocal microscopy for SKBR3 cells incu-
bated for 2 h in the presence of DOX (a), 2kPEI(DOX⊂CD)Mal (b), [2kPEI(DOX⊂CD)Mal]∼[MBP*] (c), or [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv] (d).
Fluorescence and differential interference contrast (Nomarski) images are shown. (B) Confocal microscopy for MDA-MB-231 or MDA-HER2 cells
incubated for 2 h with DOX (a) or [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv] (b). (C) Fluorescence exhibit by MDA-MB-231, SKBR3 or MDA-HER2+ cells
incubated with DOX and with Mal-based (DOX⊂CD) complexes: 2kPEI(DOX⊂CD)Mal, [2kPEI(DOX⊂CD)Mal]∼[MBP*] or [2kPEI(DOX⊂CD)
Mal]∼[MBP*-ScFv]. Cells were lysed after 2 h and DOX fluorescence measured. Results are expressed as means ± S.E.M. (n = 8). *: p < 0.05 vs. DOX
treated cells. #: p < 0.05 vs. [2kPEI(DOX⊂CD)Mal]∼[MBP*] treated cells. (D) In vitro cytotoxicity of DOX and Mal-based targeted (DOX⊂CD) inclusion
complexes. Cell viability measured using the MTT method for MDA-MB-231, MDA-HER2+ or SKBR3 cells incubated for 48 h with DOX, 2kPEI(CD)
Mal, [2kPEI(DOX⊂CD)Mal]∼[MBP*], MBP*-ScFv, [2kPEI(DOX⊂CD)Mal]∼[MBP*] or [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv]. Results are expressed as
means ± S.E.M. (n = 8). *: p < 0.05 vs. DOX treated cells; #: p < 0.05 vs. [2kPEI(DOX⊂CD)Mal]∼[MBP*] treated cells; +: p < 0.05 vs. MBP*-ScFv
treated cells.
Paper Biomaterials Science

































































































MBP*-ScFv. First, 25kPEI(Mal) was incubated with pDNA, fol-
lowed by binding the resulting 25kPEI(Mal)/pDNA polyplex
with equimolecular amounts of either MBP* or MBP*-ScFv.
The analysis of the DNA binding affinity and protection from
DNaseI showed that neither the maltosylation nor the link to
either MBP* or MBP*-ScFv had any negative effect on these
two critical features of 25kPEI (Fig. S3, ESI†). Transfection was
assayed on the HER2+ cell lines (SKBR3 and MDA-HER2+) and
MDA-MB-231 as a HER2− control, using the pEGFP-N3
plasmid encoding an enhanced red-shifted variant of wild-type
GFP. The higher transfection efficiency was attained by using
an N/P ratio of 7, as observed in optimization assays per-
formed in the three types of cells (data non-shown). The trans-
fection efficiency of native 25kPEI varied with the cell line
(Fig. 6A). While PEI maltosylation improved the performance
on MDA-HER2+, coupling to MBP* decreased the transfection
efficiency. On the contrary, as expected, the coupling to MBP*-
ScFv yielded an improvement in the transfection efficiency on
the HER2+ cell lines whereas the values of fluorescence for
MDA-MB-231 remained at the same level as those for 25kPEI.
To confirm the role of the MBP*-ScFv in the improvement
of the transfection, SKBR3 cells were pre-treated with trastuzu-
mab to block the HER2 receptor and then with [25kPEI(Mal)/
pEGFP-N3]∼[MBP*-ScFv] (Fig. 6B). The transfection efficiency
diminished as the concentration of trastuzumab in the pre-
treatment was increased, demonstrating that the improvement
in the efficiency of the transfection when the DNA is carried by
[25kPEI(Mal)]∼[MBP*-ScFv] is a consequence of the targeting
module MBP*-ScFv. In vivo experiments on NSG mice bearing
SKBR3 tumor xenografts further confirmed the potential of
[25kPEI(Mal)]∼[MBP*-ScFv] in gene delivery, the fluorescence
signal being localized in the xenograft (Fig. 6C) and the inten-
sity being 3-fold higher than that of LP (Fig. 6D).
4. Discussion
Antibody–drug conjugates represent a growing market, several
of them approved by the FDA and more than 70 candidates
currently in clinical trials.41 The technology seems simple and
the majority of antibody–drug conjugates on the market use
conjugation approaches that target naturally occurring amino
acids such as lysine (i.e. gemtuzumab ozogamicin, trastuzu-
mab emtansine, and inotuzumab ozogamicin) or interchain
cysteines (i.e. brentuximab vedotin). However, this straight-
forward approach results in a random linkage of the drug to
the antibody and yields heterogeneous mixtures with different
drug-to-antibodies-ratios that impact the physicochemical pro-
perties, pharmacokinetics, and lot-to-lot reproducibility.42 At
the cost of increasing the complexity, the next generation of
antibody–drug conjugates rely on site-specific bioconjugation
strategies such as THIOMABs technology, transglutaminase-
mediated conjugations, click chemistry conjugation, bridge
cysteine conjugations, glycosyl remodeling, to reduce the pro-
Fig. 5 In vitro and vivo targeted ICG delivery mediated by Mal-based
(ICG⊂CD) inclusion complexes. (A) Confocal microscopy images for
SKBR3 cells incubated in the presence of [2kPEI(ICG⊂CD)Mal]∼[MBP*]
(a) or [2kPEI(ICG⊂CD)Mal]∼[MBP*-ScFv] (b). Fluorescence and differen-
tial interference contrast (Nomarski) images are shown. (B) NSG mice
bearing breast cancer HER2+ (SKBR3 cells) tumors injected intra-
venously in the tail vein with [2kPEI(ICG⊂CD)Mal]∼[MBP*] or [2kPEI
(ICG⊂CD)Mal]∼[MBP*-ScFv]. Fluorescence distribution was measured
3 h later. Size of the xenografts is indicated by a dotted line. (C) Average
radiance plotting of the xenografts from the mice injected with [2kPEI
(ICG⊂CD)Mal]∼[MBP*] or [2kPEI(ICG⊂CD)Mal]∼[MBP*-ScFv]. Data are
shown as means ± SEM (n = 4). *p < 0.05 vs. [2kPEI(ICG⊂CD)
Mal]∼[MBP*] xenografts.
Fig. 6 Targeted gene delivery to HER2 bearing cells mediated by
MBP*-ScFv based polyplexes. (A) In vitro transfection efficiency of
[25kPEI(Mal)/pDNA]∼[MBP*] and [25kPEI(Mal)/pDNA]∼[MBP*-ScFv]
polyplex in HER2+ (SKBR3 and MDA-HER) and HER2− (MDA-MB-231)
breast cancer cells. N = 8. * p < 0.5 compared to 25kPEI; # p < 0.5 com-
pared to 25kPEI(Mal)∼[MBP*]. (B) Fluorescence values for SKBR3 cells
pre-incubated with increasing concentrations of herceptin (30 min) and
transfected with [25kPEI(Mal/pEGFP-N3)]∼[MBP*-ScFv] polyplex.
Fluorescence values in the absence of herceptin have been normalized
to 100%. * p < 0.5 compared with control transfection. (C) In vivo trans-
fection for NSG mice bearing SKBR3 tumor-xenografts. Images were
taken 24 h after LP/pGL3 or [25kPEI(Mal)/pGL3]∼[MBP*-ScFv] poly-
plexes intravenous injection in the tail vein. The size of the xenografts is
indicated by a dotted line. (D) The average radiance of the xenografts
from the mice injected with LP/pGL3 or [25kPEI(Mal)/pGL3]∼[MBP*-
ScFv] polyplexes is plotted. Data are shown as means ± SEM (n = 4). *p <
0.05 vs. LP/pGL3 xenographs.
Biomaterials Science Paper

































































































blems associated with heterogeneity and to enable antibody-
like fragments to improve tumor penetration.
Inspired by the biotin–(strept)avidin technology43 and the
long history of the MBP as a tag that enhances the
solubility29,30 and overexpression of recombinant proteins in
both E. coli and mammalian cells,44 we envisaged a strategy of
bioconjugation based on the overexpression of antibody-like
fragments as MBP fusion proteins which, besides the afore-
mentioned benefits,33,34,45,46 act as an attachment point for
elements conveniently functionalized with a maltose moiety
(Fig. 1A). As a proof of concept, we designed a construct con-
taining an ScFv as a targeting element, a His-tag (6xHis-tag) as
an affinity tag for purification, and the enhanced maltose
affinity MBP I334W tag as the attachment point. An ScFv
directed toward the human epidermal growth factor receptor 2
(HER2) was selected based on its relevance, on the fact that
HER2 overexpression is associated with poor outcomes in
breast and gastric cancer and on its key role in activating the
downstream signaling pathways that control cell proliferation,
survival, and apoptosis in breast cancer.27,47–49 Trastuzumab, a
mAb that inhibits HER2 and is currently being exploited for
targeting, was the first mAb approved for human use. It is the
cornerstone of HER2+ breast cancer treatment despite the fact
that other anti-HER2 Ab targeting the extracellular domain
have been described.50–52
As expected from the MBP tag, the overexpression of the
construct in E. coli rendered a soluble MBP*-ScFv which, after
purification by IMAC chromatography, yields 0.5 mg L−1 of
culture media. MBP*-ScFv bears a double functionality: ScFv
being as selective towards cell lines that express HER2 as tras-
tuzumab (Fig. 1B), and MBP* as a feasible attachment point of
maltosylated elements. Our strategy was validated using
[(IR783)Mal]∼[MBP*-ScFv], a complex resulting from the mal-
tosylation of the NIR dye IR783 and later in combination with
MBP*-ScFv. Furthermore, [(IR783)Mal]∼[MBP*-ScFv] could be
clinically useful since the determination of Her2 expression
levels is a prognostic biomarker for anti-HER2 treatment in a
variety of tumor types including breast, gastric and gynecologi-
cal cancers. In this context, [(IR783)Mal]∼[MBP*-ScFv] com-
bines the selectivity to target HER2+ cells with the NIR emis-
sion of IR783, features that suggest a medical application in
diagnosis.53 Nevertheless, although the selectivity toward
cancer cells overexpressing HER2 could be compromised by
the well-established affinity of IR783 for tumor cells or the
interaction between (IR783)Mal and MBP*-ScFv could be dis-
rupted in a biological environment, our in vitro experiments
demonstrated that interaction is stable and that [(IR783)
Mal]∼[MBP*-ScFv] shows a 5.7-fold-higher affinity for HER+
cells (Fig. 2), supporting a further evaluation in vivo on a xeno-
graft model of HER2+ adenocarcinoma obtained by injection
of SKBR3 cells in mice. In agreement with the general affinity
of IR783 for tumor compound (IR783), Mal is found in the
xenograft although the signal is more intense for [(IR783)
Mal]∼[MBP*-ScFv], as expected from the targeting toward
HER2 receptor (Fig. 3). It is important to recall that the poten-
tial of [(IR783)Mal]∼[MBP*-ScFv] may exceed the diagnosis
application evaluated in this work since the reported thera-
peutic action of IR783 as an inhibitor of cancer cell prolifer-
ation54 and in phototherapy55 supports the use of [(IR783)
Mal]∼[MBP*-ScFv] in theragnosis.
A key point in cancer therapy is dosage. Unfortunately,
large doses, while ensuring therapeutic action, are associated
with pronounced side effects. An interesting alternative is the
design of methods for site-directed drug delivery where the
amount of drug delivered to the site of action by antibody–
drug conjugates is proportional to the number of receptors tar-
geted. The increase in the drug–antibody ratio has been a clas-
sical approach not exempt from drawbacks, since it often
affects pharmacokinetics and the increase of hydrophobicity is
frequently one of the key factors to be considered.42,56 To
approach this challenge and inspired by a previous work that
demonstrated the feasibility of using a nanobody-cyclodextrin
conjugate as a site-directed drug delivery system,37 we envi-
sioned a modular design where the targeting module bears the
MBP and the carrier module is maltosylated. As a proof of
concept, PEI was functionalized with maltose and with
β-cyclodextrin to obtain a multivalent platform that exploits
the ability of cyclodextrin to form inclusion complexes with
hydrophobic molecules such as chemotherapeutic anticancer
drugs57 and the interaction of the maltose with MBP*-ScFv to
yield the complex [2kPEI(CD)Mal]∼[MBP*-ScFv]. DOX was
selected as a model drug for the evaluation of the complex
because it shows a wide range of antitumor activity, being
broadly used in cancer treatment. However, its potential is
limited by cardiotoxicity, and the development of other ways to
manage DOX is a challenge. In vitro experiments demonstrated
that the uptake of DOX by HER2+ cells is higher when DOX is
delivered as [2kPEI(DOX⊂CD)Mal]∼[MBP*-ScFv] and this
effect measured as cytotoxicity was dependent on the
expression HER2+ (Fig. 4). The In vivo evaluation using the
diagnostic dye indocyanine green further confirmed the site-
directed drug delivery capability of [2kPEI(ICG⊂CD)
Mal]∼[MBP*-ScFv] (Fig. 5). In vivo assays indicate that the
MBP*-ScFv platform is able to specifically target these xeno-
graphs, although some leaking of the ICG compound to liver
takes place. This finding points to a partial dissociation of the
complex that could be prevented in future developments by
incorporating additional mutations into the MBP to increase
its binding affinity for the maltosylated ligands.58 At this
point, it is important to highlight the flexibility of [2kPEI(CD)
Mal]∼[MBP*-ScFv] as a carrier of a wide range of molecules
since the payload is only limited by the affinity towards CD to
yield an inclusion complex.
Currently, cancer treatment relies on chemotherapy, radio-
therapy and surgery as a multimodal therapy that often does
not suffice to reverse the progress of cancer. The increasing
advances in the knowledge of the characteristics of tumor cells
and their microenvironment have led to novel therapeutic
approaches based on gene therapy.59 However, the develop-
ment of delivery systems that efficiently deliver genes to
specific target tissues with minimal toxicity and immunogeni-
city remains a challenge. Nonviral vectors are an alternative to
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the immune and toxic side effects of viral vectors and among
them branched 25kPEI acts as an efficient transfection agent.
25kPEI has been conjugated to trastuzumab for gene delivery60
but we hypothesized that our simpler and more versatile
approach of bioconjugation could be used to transfect HER2+
cells. Our results demonstrate that the maltosylation of PEI
25k has no negative effect either on the affinity by DNA or the
protection against DNaseI and it is a straightforward strategy
to extend the application of MBP*-ScFv to deliver genes to
HER2+ cells in vitro (Fig. 5) and in vivo (Fig. 6).
5. Conclusions
The interest in the widely used strategy of cloning the protein
of interest into a plasmid encoding the MBP tag can be
extended beyond its overexpression and purification. We have
demonstrated that the MBP tag is an attachment point for mal-
tosylated elements and that the use of the maltose-MBP inter-
action is a feasible bioconjugation strategy. In cancer therapy,
antibody–drug conjugates represent a new generation of drugs
and in this context, new strategies of bioconjugation are
needed to overcome the limitations of those currently used.
Our results demonstrate that the overexpression of a ScFv as a
fusion protein with MBP transforms it into a versatile targeting
element that can be combined with different carrier modules
for in vivo diagnosis, site-directed drug delivery, and receptor-
mediated gene therapy. This modular approach simplifies the
design of antibody–drug conjugates and its implementation is
feasible in standard molecular biology laboratories.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
This work was supported by grants CTQ2014-55474-C2-1-R,
CTQ2014-55474-C2-2-R and CTQ2017-86125-P from the
Ministerio Economia, Industria y Competitividad (co-financed
by FEDER funds). SP is supported by a FPU fellowship (FPU17/
04749). We acknowledge the University of Granada (Spain) cell
culture, animal and microscopy central facilities (CIC-UGR).
Notes and references
1 A. Wicki, D. Witzigmann, V. Balasubramanian and
J. Huwyler, J. Controlled Release, 2015, 200, 138–157.
2 V. K. Chaturvedi, A. Singh, V. K. Singh and M. P. Singh,
Curr. Drug Metab., 2019, 20, 416–429.
3 S. Tran, P. J. DeGiovanni, B. Piel and P. Rai, Clin. Transl.
Med., 2017, 6, 44.
4 V. J. Yao, S. D’Angelo, K. S. Butler, C. Theron, T. L. Smith,
S. Marchio, J. G. Gelovani, R. L. Sidman, A. S. Dobroff,
C. J. Brinker, A. R. M. Bradbury, W. Arap and R. Pasqualini,
J. Controlled Release, 2016, 240, 267–286.
5 N. Bertrand, J. Wu, X. Xu, N. Kamaly and O. C. Farokhzad,
Adv. Drug Delivery Rev., 2014, 66, 2–25.
6 L. Lu, W. Chen and Z. Sun, Angew. Chem., Int. Ed., 2020, 59,
2–20.
7 A. Carvalho, A. R. Fernandes and P. V. Baptista, in
Applications of Targeted Nano Drugs and Delivery Systems,
2019, pp. 257–295, DOI: 10.1016/b978-0-12-814029-1.00010-
7.
8 M. Sharma, C. Pandey, N. Sharma, M. A. Kamal, U. Sayeed
and S. Akhtar, Anticancer Agents Med. Chem., 2018, 18,
2078–2092.
9 P. Y. Liyanage, S. D. Hettiarachchi, Y. Zhou, A. Ouhtit,
E. S. Seven, C. Y. Oztan, E. Celik and R. M. Leblanc,
Biochim. Biophys. Acta, Rev. Cancer, 2019, 1871, 419–433.
10 J. M. Lambert and A. Berkenblit, Annu. Rev. Med., 2018, 69,
191–207.
11 M. R. Gordon, M. Canakci, L. Li, J. Zhuang, B. Osborne
and S. Thayumanavan, Bioconjugate Chem., 2015, 26, 2198–
2215.
12 A. Alibakhshi, K. F. Abarghooi, S. Ahangarzadeh,
H. Yaghoobi, F. Yarian, R. Arezumand, J. Ranjbari,
A. Mokhtarzadeh and M. de la Guardia, J. Controlled
Release, 2017, 268, 323–334.
13 V. Crivianu-Gaita and M. Thompson, Biosens. Bioelectron.,
2016, 85, 32–45.
14 Z. A. Ahmad, S. K. Yeap, A. M. Ali, W. Y. Ho,
N. B. M. Alitheen and M. Hamid, Clin. Dev. Immunol., 2012,
2012, 980250.
15 P. Thanindratarn, D. C. Dean, S. D. Nelson, F. J. Hornicek
and Z. Duan, Cancer Treat. Rev., 2020, 82, 101934.
16 A. C. Marques, P. J. Costa, S. Velho and M. H. Amaral,
J. Controlled Release, 2020, 320, 180–200.
17 O. M. Kutova, E. L. Guryev, E. A. Sokolova, R. Alzeibak and
I. V. Balalaeva, Cancers, 2019, 11, 68.
18 P. Zhang, H. Chen, J. Liu and G. Liu, Methods Mol. Biol.,
2019, 2054, 283–294.
19 C. Q. Bie, D. H. Yang, X. J. Liang and S. H. Tang, World J.
Hepatol., 2010, 2, 185–191.
20 C. L. Parker, Q. Yang, B. Yang, J. D. McCallen, S. I. Park
and S. K. Lai, Acta Biomater., 2017, 63, 181–189.
21 Q. Yang, C. L. Parker, Y. Lin, O. W. Press, S. I. Park and
S. K. Lai, J. Controlled Release, 2017, 255, 73–80.
22 A. Sarker, A. S. Rathore and R. D. Gupta, Microb. Cell Fact.,
2019, 18, 5.
23 H. Bach, Y. Mazor, S. Shaky, A. Shoham-Lev,
Y. Berdichevsky, D. L. Gutnick and I. Benhar, J. Mol. Biol.,
2001, 312, 79–93.
24 R. Birnboim-Perach, Y. Grinberg, L. Vaks, L. Nahary and
I. Benhar, Methods Mol. Biol., 2019, 1904, 455–480.
25 F. J. Lopez-Jaramillo, M. Ortega-Muñoz, A. Megia-
Fernandez, F. Hernandez-Mateo and F. Santoyo-Gonzalez,
Bioconjugate Chem., 2012, 23, 846–855.
26 J. Morales-Sanfrutos, J. Lopez-Jaramillo, M. Ortega-Munoz,
A. Megia-Fernandez, F. Perez-Balderas, F. Hernandez-Mateo
Biomaterials Science Paper

































































































and F. Santoyo-Gonzalez, Org. Biomol. Chem., 2010, 8, 667–
675.
27 E. Song, P. Zhu, S. K. Lee, D. Chowdhury, S. Kussman,
D. M. Dykxhoorn, Y. Feng, D. Palliser, D. B. Weiner,
P. Shankar, W. A. Marasco and J. Lieberman, Nat.
Biotechnol., 2005, 23, 709–717.
28 M. Torres, S. Uroz, R. Salto, L. Fauchery, E. Quesada and
I. Llamas, Sci. Rep., 2017, 7, 943.
29 M. Kucinska, M. D. Giron, H. Piotrowska, N. Lisiak,
W. H. Granig, F. J. Lopez-Jaramillo, R. Salto, M. Murias and
T. Erker, PLoS One, 2016, 11, e0145615.
30 H. Greulich, B. Kaplan, P. Mertins, T. H. Chen,
K. E. Tanaka, C. H. Yun, X. Zhang, S. H. Lee, J. Cho,
L. Ambrogio, R. Liao, M. Imielinski, S. Banerji,
A. H. Berger, M. S. Lawrence, J. Zhang, N. H. Pho,
S. R. Walker, W. Winckler, G. Getz, D. Frank, W. C. Hahn,
M. J. Eck, D. R. Mani, J. D. Jaffe, S. A. Carr, K. K. Wong and
M. Meyerson, Proc. Natl. Acad. Sci. U. S. A., 2012, 109,
14476–14481.
31 J. Morales-Sanfrutos, F. J. Lopez-Jaramillo, F. Hernandez-
Mateo and F. Santoyo-Gonzalez, J. Org. Chem., 2010, 75,
4039–4047.
32 E. De Los Reyes-Berbel, R. Salto-Gonzalez, M. Ortega-
Munoz, F. J. Reche-Perez, A. B. Jodar-Reyes, F. Hernandez-
Mateo, M. D. Giron-Gonzalez and F. Santoyo-Gonzalez,
Bioconjugate Chem., 2018, 29, 2561–2575.
33 M. D. Giron-Gonzalez, R. Salto-Gonzalez, F. J. Lopez-
Jaramillo, A. Salinas-Castillo, A. B. Jodar-Reyes, M. Ortega-
Munoz, F. Hernandez-Mateo and F. Santoyo-Gonzalez,
Bioconjugate Chem., 2016, 27, 549–561.
34 M. E. Kimple, A. L. Brill and R. L. Pasker, Curr. Protoc.
Protein Sci., 2013, 73, 9.9.1–9.9.23.
35 E. De Los Reyes-Berbel, R. Salto-Gonzalez, M. Ortega-
Munoz, F. J. Reche-Perez, A. B. Jodar-Reyes, F. Hernandez-
Mateo, M. D. Giron-Gonzalez and F. Santoyo-Gonzalez,
Bioconjugate Chem., 2018, 29, 2561–2575.
36 T. C. Hou, Y. Y. Wu, P. Y. Chiang and K. T. Tan, Chem. Sci.,
2015, 6, 4643–4649.
37 T. del Castillo, J. Marales-Sanfrutos, F. Santoyo-Gonzalez,
S. Magez, F. J. Lopez-Jaramillo and J. A. Garcia-Salcedo,
ChemMedChem, 2014, 9, 383–389.
38 T. Yousef and N. Hassan, J. Inclusion Phenom. Macrocyclic
Chem., 2017, 87, 105–115.
39 M. V. Marshall, J. C. Rasmussen, I. C. Tan, M. B. Aldrich,
K. E. Adams, X. Wang, C. E. Fife, E. A. Maus, L. A. Smith
and E. M. Sevick-Muraca, Open Surg. Oncol. J., 2010, 2, 12–25.
40 X. Wang, D. Niu, C. Hu and P. Li, Curr. Pharm. Des., 2015,
21, 6140–6156.
41 A. Beck, L. Goetsch, C. Dumontet and N. Corvaia, Nat. Rev.
Drug Discovery, 2017, 16, 315–337.
42 J. W. Buecheler, M. Winzer, C. Weber and H. Gieseler,
J. Pharm. Sci., 2020, 109, 161–168.
43 C. M. Dundas, D. Demonte and S. Park, Appl. Microbiol.
Biotechnol., 2013, 97, 9343–9353.
44 R. Reuten, D. Nikodemus, M. B. Oliveira, T. R. Patel,
B. Brachvogel, I. Breloy, J. Stetefeld and M. Koch, PLoS One,
2016, 11, e0152386.
45 D. S. Waugh, Postepy Biochem., 2016, 62, 377–382.
46 P. Sun, J. E. Tropea and D. S. Waugh, Methods Mol. Biol.,
2011, 705, 259–274.
47 R. Schier, A. McCall, G. P. Adams, K. W. Marshall,
H. Merritt, M. Yim, R. S. Crawford, L. M. Weiner, C. Marks
and J. D. Marks, J. Mol. Biol., 1996, 263, 551–567.
48 M. M. Moasser, Oncogene, 2007, 26, 6469–6487.
49 S. Parakh, H. K. Gan, A. C. Parslow, I. J. G. Burvenich,
A. W. Burgess and A. M. Scott, Cancer Treat. Rev., 2017, 59,
1–21.
50 J. Albanell and J. Baselga, Drugs Today, 1999, 35, 931–946.
51 M. Mahdavi, M. Keyhanfar, A. Jafarian, H. Mohabatkar and
M. Rabbani, Monoclonal Antibodies Immunodiagn.
Immunother., 2015, 34, 213–221.
52 C. Ceran, M. Cokol, S. Cingoz, I. Tasan, M. Ozturk and
T. Yagci, BMC Cancer, 2012, 12, 450.
53 X. Yang, C. Shi, R. Tong, W. Qian, H. E. Zhau, R. Wang,
G. Zhu, J. Cheng, V. W. Yang, T. Cheng, M. Henary,
L. Strekowski and L. W. Chung, Clin. Cancer Res., 2010, 16,
2833–2844.
54 P. Li, Y. Liu, W. Liu, G. Li, Q. Tang, Q. Zhang, F. Leng,
F. Sheng, C. Hu, W. Lai, Y. Liu, M. Zhou, J. Huang,
H. Zhou, R. Zhang and Y. Zhao, Int. J. Oncol., 2019, 55,
415–424.
55 T. Duong, X. Li, B. Yang, C. Schumann, H. A. Albarqi,
O. Taratula and O. Taratula, Nanomedicine, 2017, 13, 955–
963.
56 K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. Sun,
J. Lenox, C. G. Cerveny, K. M. Kissler, S. X. Bernhardt,
A. K. Kopcha, R. F. Zabinski, D. L. Meyer and
J. A. Francisco, Clin. Cancer Res., 2004, 10, 7063–7070.
57 B. Tian, S. Hua and J. Liu, Carbohydr. Polym., 2020, 232,
115805.
58 J. S. Marvin and H. W. Hellinga, Nat. Struct. Biol., 2001, 8,
795–798.
59 C. Roma-Rodrigues, L. Rivas-Garcia, P. V. Baptista and
A. R. Fernandes, Pharmaceutics, 2020, 12(3), 233.
60 O. Germershaus, T. Merdan, U. Bakowsky, M. Behe and
T. Kissel, Bioconjugate Chem., 2006, 17, 1190–1199.
Paper Biomaterials Science
1738 | Biomater. Sci., 2021, 9, 1728–1738 This journal is © The Royal Society of Chemistry 2021
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 0
4 
Ja
nu
ar
y 
20
21
. D
ow
nl
oa
de
d 
on
 5
/6
/2
02
1 
7:
33
:3
0 
A
M
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Online
